Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABOGO trial of alternative antibiotics for uncomplicated anogenital gonorrhea
NL-OMON49273Phase 3Active, not recruiting
- Sponsor
- Amsterdam UMC Department of Dermatology
- Start
- Sep 2017
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftriaxone, ertapenem, gentamicin and fosfomycin in gonorrhea (4 arms), sponsored by Amsterdam UMC Department of Dermatology. Primary endpoint: Bacterial eradication at included infection site at 7-14 days. Started Sep 2017; status: active, not recruiting.
02
Drugs
ceftriaxoneertapenemgentamicinfosfomycin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NL-OMON49273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49273.